pharmaphorum

DECEMBER 24, 2020

Forxiga (dapagliflozin) – originally developed as a type 2 diabetes drug – is the first SGLT2 inhibitor to be approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without diabetes. billion, assuming a launch for HFrEF in 2021.

Diabetes 98

Diabetes 98

pharmaphorum

AUGUST 9, 2021

The European Commission has cleared Forxiga (dapagliflozin) for CKD in adults with or without diabetes, and the drug becomes the first new drug treatment for these patients in more than two decades. GlobalData has said Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6

Diabetes 111

Diabetes 111

pharmaphorum

JUNE 22, 2021

Jardiance, Farxiga (dapagliflozin) and other SGLT2 drugs are already widely used to treat type 2 diabetes, and their developers have long had aspirations to expand their use into other cardiometabolic disorders, including heart failure and chronic kidney disease (CKD).

Diabetes 98

Diabetes 98

Express Pharma

MAY 30, 2024

million in 2023 to 9 million in 2028. In the APAC region, several factors contribute to the increasing prevalence of neurological disorders, including ageing populations, lifestyle changes, and the rising incidence of risk factors such as hypertension and diabetes.” per cent from 7.45 These include Eisai Co.

Compounding 114

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 114

pharmaphorum

JANUARY 12, 2021

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. It says Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6

Labelling 70

Labelling Diabetes 70

European Pharmaceutical Review

AUGUST 21, 2023

Its diabetes treatment Mounjaro led this outcome. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. billion to revenue in Q2 2023. billion in Q2 2023. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1

Biosimilars 98

Biosimilars Diabetes Vaccines 98

Express Pharma

SEPTEMBER 12, 2023

HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028. As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH. tumor formation, immune reactions, and therapy failure).

Diabetes 111

Diabetes Immunity Immunization 111

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga. Jardiance is also used to reduce cardiovascular complications in diabetic patients. billion in the first half of 2021.

Diabetes 52

Diabetes 52

Express Pharma

AUGUST 22, 2023

Lilly’s strong market capitalisation growth over Q2 was attributed to its diabetes drug Mounjaro, a synthetic peptide that reported $980 million in global sales, according to GlobalData’s Pharmaceutical Intelligence Center Drugs Database. per cent increase in market capitalisation.” billion by 2029, according to GlobalData’s Drugs Database.

Biosimilars 94

Biosimilars Diabetes 94

pharmaphorum

OCTOBER 10, 2022

Keytruda is due to lose patent protection in around 2028, and the threat of generic competition to it and other top sellers like type 2 diabetes therapy Januvia (sitagliptin) gives it one of the steeper patent cliffs among to-tier pharma groups.

Diabetes 52

Diabetes 52

Fuld & Company Blog

MARCH 27, 2023

The background of semaglutide Nearly 20 years ago the first glucagon-like peptide 1 (GLP-1), a class of Type 2 diabetes drug that improves blood sugar, was launched, creating what is today a market worth nearly $30B. This market was estimated to be worth over $80 billion, in addition to the $30 billion diabetes market.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

PharmaShots

JUNE 21, 2023

The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028 The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs. from various breeds or breed mixes. in (SCORED).

Hospitals 40

Hospitals Diabetes 40